<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-archivearticle1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4190355</article-id><article-id pub-id-type="pmid">25295591</article-id><article-id pub-id-type="publisher-id">PONE-D-14-31817</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0110061</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Biology and Life Sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>Genomics</subject><subj-group><subject>Genomic Medicine</subject><subj-group><subject>Genetic Testing</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine and Health Sciences</subject><subj-group><subject>Clinical Genetics</subject><subj-group><subject>Genetic Diseases</subject></subj-group></subj-group><subj-group><subject>Oncology</subject><subj-group><subject>Cancer Risk Factors</subject><subject>Carcinogenesis</subject><subject>Carcinogens</subject></subj-group></subj-group></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>Role of IL-4 Gene Polymorphisms in HBV-Related Hepatocellular Carcinoma in a Chinese Population </plain></SENT>
</text></SecTag></article-title><alt-title alt-title-type="running-head"><italic>IL-4</italic> Gene Polymorphisms and HBV-Related Hepatocellular Carcinoma Risk</alt-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Lu</surname><given-names>Yu</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Wu</surname><given-names>Zhitong</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Peng</surname><given-names>Qiliu</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Ma</surname><given-names>Liping</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Xiaolian</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Zhao</surname><given-names>Jiangyang</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Qin</surname><given-names>Xue</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="corresp" rid="cor1">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Shan</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="corresp" rid="cor1">
<sup>*</sup>
</xref></contrib></contrib-group><aff id="aff1">
<label>1</label>
<addr-line>Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China</addr-line>
</aff><aff id="aff2">
<label>2</label>
<addr-line>Department of Clinical Laboratory, Guigang People’s Hospital, Guigang, Guangxi, China</addr-line>
</aff><contrib-group><contrib contrib-type="editor"><name><surname>Coleman</surname><given-names>William B.</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">
<addr-line>University of North Carolina School of Medicine, United States of America</addr-line>
</aff><author-notes><corresp id="cor1">* E-mail: <email>qinxue919@126.com</email> (XQ); <email>lis8858@126.com</email> (SL)</corresp><fn fn-type="COI-statement"><p><text><SENT sid="1" pm="."><plain>Competing Interests: The authors have declared that no competing interests exist. </plain></SENT>
</text></p></fn><fn fn-type="con"><p><text><SENT sid="2" pm="."><plain>Conceived and designed the experiments: XQ SL. </plain></SENT>
<SENT sid="3" pm="."><plain>Performed the experiments: YL ZTW. </plain></SENT>
<SENT sid="4" pm="."><plain>Analyzed the data: QLP LPM. </plain></SENT>
<SENT sid="5" pm="."><plain>Contributed reagents/materials/analysis tools: XLZ JYZ. </plain></SENT>
<SENT sid="6" pm="."><plain>Contributed to the writing of the manuscript: YL. </plain></SENT>
</text></p></fn></author-notes><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>8</day><month>10</month><year>2014</year></pub-date><volume>9</volume><issue>10</issue><elocation-id>e110061</elocation-id><history><date date-type="received"><day>26</day><month>7</month><year>2014</year></date><date date-type="accepted"><day>8</day><month>9</month><year>2014</year></date></history><permissions><copyright-statement>© 2014 Lu et al</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>Lu et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.</license-p></license></permissions><abstract><sec><title><text><SENT sid="7" pm="."><plain>Background </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="8" pm="."><plain>Interleukin-4 (IL-4) is best known as an important mediator and modulator of immune and inflammatory responses. </plain></SENT>
<SENT sid="9" pm="."><plain>Hepatocellular carcinoma (HCC) is a typical inflammation-related cancer, and genetic variations in the IL-4 gene may be associated with the risk of hepatitis B virus (HBV)-related HCC. </plain></SENT>
<SENT sid="10" pm="."><plain>However, few studies have been conducted on their association. </plain></SENT>
</text></SecTag></p></sec><sec><title><text><SENT sid="11" pm="."><plain>Objectives </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="12" pm="."><plain>To clarify the effects of IL-4 gene polymorphisms on the risk of HBV-related HCC, two common variants, −590C/T (rs2243250) and −33C/T (rs2070874), and their relationship with HBV-related disease risk were investigated in a Chinese population. </plain></SENT>
</text></SecTag></p></sec><sec><title><text><SENT sid="13" pm="."><plain>Methods </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="14" pm="."><plain>IL-4 −590C/T and −33C/T polymorphisms were examined in 154 patients with HBV-related HCC, 62 patients with HBV-induced liver cirrhosis (LC), 129 patients with chronic hepatitis B (CHB), and 94 healthy controls, using the polymerase chain reaction-restriction fragment length polymorphism method and DNA sequencing. </plain></SENT>
</text></SecTag></p></sec><sec><title><text><SENT sid="15" pm="."><plain>Results </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="16" pm="."><plain>Overall, no significant differences were observed regarding the IL-4 −590C/T and −33C/T polymorphism genotypes, alleles, or haplotypes between the patient groups and the healthy controls. </plain></SENT>
<SENT sid="17" pm="."><plain>However, the CC genotypes of IL-4 −590C/T and −33C/T polymorphisms were observed to be significantly associated with CHB in subgroup analysis in males [CC versus TT (OR: 4.193, 95% CI: 1.094–16.071, P = 0.037; and OR: 3.438, 95% CI: 1.032–11.458, P = 0.044) and CC versus TT+CT (OR: 4.09, 95% CI: 1.08–15.49, P = 0.038; and OR: 3.43, 95% CI: 1.04–11.28, P = 0.042)]. </plain></SENT>
</text></SecTag></p></sec><sec><title><text><SENT sid="18" pm="."><plain>Conclusions </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="19" pm="."><plain>These findings suggest that genetic variants in IL-4 −590C/T and −33C/T polymorphisms may be a risk factor for CHB in Chinese males but not for HBV-related LC or HCC. </plain></SENT>
</text></SecTag></p></sec></abstract><funding-group><funding-statement>This research was supported by National Natural Science Foundation of China (No. 81260302) and Youth Science Foundation of Guangxi Medical University (GXMUYSF201334). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><page-count count="10"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>The authors confirm that all data underlying the findings are fully available without restriction. All relevant data are within the paper and its Supporting Information files.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>The authors confirm that all data underlying the findings are fully available without restriction. All relevant data are within the paper and its Supporting Information files.</p></notes></front><body><SecTag type="INTRO"><sec id="s1"><title><text><SENT sid="20" pm="."><plain>Introduction </plain></SENT>
</text></title><p><text><SENT sid="21" pm="."><plain>Hepatitis B virus (HBV) infection is one of the leading causes of liver disease, with more than 2 billion people infected worldwide [1], [2]. </plain></SENT>
<SENT sid="22" pm="."><plain>Among them, approximately 350 million individuals persistently infected with HBV develop chronic hepatitis, which results in liver cirrhosis (LC) in one third of all cases, more than three quarters of which progress to hepatocellular carcinoma (HCC) [3]. </plain></SENT>
<SENT sid="23" pm="."><plain>It is widely accepted that chronic hepatitis B (CHB), LC, and HCC are progressive stages of chronic HBV infection [4]. </plain></SENT>
<SENT sid="24" pm="."><plain>Nevertheless, the mechanisms underlying such progression are not yet well understood, although immune system-mediated chronic inflammation is believed to play a pivotal role in HCC development. </plain></SENT>
<SENT sid="25" pm="."><plain>HBV clearance depends on an effective host immune response [5] and, thus, ineffective host immunity may create a hepatocarcinogenic microenvironment in the presence of HBV infection [6]–[8]. </plain></SENT>
</text></p><p><text><SENT sid="26" pm="."><plain>Interleukin-4 (IL-4), a multifunctional pleiotropic cytokine mainly produced by activated T helper 2 (Th2) cells, plays important roles as a mediator and modulator of immune and inflammatory responses [9]; it is not only involved in humoral and cell-mediated immunity, but also an essential regulator in the immune response of B cells, T cells, and macrophages to fight against infections and malignant cells [10]; Th2 diseases are, in their majority, driven by IL-4 [11]. </plain></SENT>
<SENT sid="27" pm="."><plain>In addition, IL-4 and IL-13 are the archetypal inducers of M2 [12]- an alternatively activated macrophage [13] that has been proved to promote HCC development [14]. </plain></SENT>
<SENT sid="28" pm="."><plain>Any alterations that influence the expression and function of IL-4 can lead to weakened immune responses, and thus increase the susceptibility to infections and inflammation-related diseases [15]. </plain></SENT>
<SENT sid="29" pm="."><plain>Due to their highly polymorphic nature, genetic mutations in this gene might be the major contributor. </plain></SENT>
</text></p><p><text><SENT sid="30" pm="."><plain>The human IL-4 gene is located on chromosome 5q31 and consists of 25 kbps [16]. </plain></SENT>
<SENT sid="31" pm="."><plain>So far, more than 50 allelic variant polymorphisms have been found (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/">http://www.ncbi.nlm.nih.gov/SNP/</ext-link>), including −590C/T (rs2243250), −33C/T (rs2070874), +3437C/G (rs2227282), and 2979G/T (rs2227284) [17]. </plain></SENT>
<SENT sid="32" pm="."><plain>The impact of IL-4 gene polymorphisms in the pathogenesis of HBV infection has been investigated, and numerous studies have suggested that IL-4 variants play pivotal roles in hepatitis B vaccine response and HBV infection risk [18]–[21]. </plain></SENT>
<SENT sid="33" pm="."><plain>However, to date, few studies have been conducted to investigate the role of these polymorphisms in HCC development [22]. </plain></SENT>
<SENT sid="34" pm="."><plain>In the present study, the two most common promoter polymorphisms of IL-4, −590C/T (rs2243250) and −33C/T (rs2070874), were evaluated in four Chinese patient groups – patients with CHB, LC, and HBV-related HCC, and a healthy control group – to determine whether these IL-4 gene polymorphisms contribute to the susceptibility of HBV-related HCC. </plain></SENT>
</text></p></sec></SecTag><SecTag type="METHODS"><sec sec-type="materials|methods" id="s2"><title><text><SENT sid="35" pm="."><plain>Materials and Methods </plain></SENT>
</text></title><sec id="s2a"><title><text><SENT sid="36" pm="."><plain>Study population </plain></SENT>
</text></title><p><text><SENT sid="37" pm="."><plain>A hospital-based series of 345 unrelated patients were recruited from the First Affiliated Hospital of Guangxi Medical University (Guangxi, China) between June and November 2013, including 154 patients with HBV-related HCC, 62 patients with HBV-induced LC, and 129 patients with CHB. </plain></SENT>
<SENT sid="38" pm="."><plain>To confirm that all patients had a chronic HBV infection for a period of at least 6 months, hepatitis B surface antigen (HBsAg), hepatitis B virus core antibody, and hepatitis Be antigen or hepatitis Be antibody were confirmed as seropositive. </plain></SENT>
<SENT sid="39" pm="."><plain>CHB was further diagnosed with serum HBV-DNA levels &gt;1,000 copies/mL, as well as elevated alanine aminotransferase or aspartate aminotransferase (&gt;2 times the upper limit of normal) [23]. </plain></SENT>
<SENT sid="40" pm="."><plain>LC was diagnosed by histologic analysis of liver biopsy specimens or typical morphologic findings from computed tomography or ultrasonography, together with laboratory features. </plain></SENT>
<SENT sid="41" pm="."><plain>For the HCC group, the patients enrolled fulfilled the following criteria: i) positive cytologic or pathologic findings or ii) elevated α-fetoprotein levels (≥400 ng/mL) combined with a positive image on computed tomography or ultrasonography; iii) were newly diagnosed HCC patients without a prior medical history of HCC; and iv) not diagnosed with other cancers [24]. </plain></SENT>
<SENT sid="42" pm="."><plain>For comparison, 170 HBV free healthy controls were randomly selected from the Health Examination Center of the First Affiliated Hospital of Guangxi Medical University during the same period. </plain></SENT>
<SENT sid="43" pm="."><plain>The selection criteria for controls were absence of any malignancy or other serious illness, as well as other inflammatory status such as autoimmune hepatitis which may generate possible bais. </plain></SENT>
<SENT sid="44" pm="."><plain>All subjects were Chinese from the Guangxi District. </plain></SENT>
<SENT sid="45" pm="."><plain>Written informed consent was obtained from each participant, and the study was approved by the ethics committee of the First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China. </plain></SENT>
</text></p></sec><sec id="s2b"><title><text><SENT sid="46" pm="."><plain>DNA extraction and single nucleotide polymorphism (SNP) genotyping </plain></SENT>
</text></title><p><text><SENT sid="47" pm="."><plain>By using the standard phenol-chloroform method, genomic DNA was extracted from 2 mL peripheral white blood cells. </plain></SENT>
<SENT sid="48" pm="."><plain>The −589C/T and −33C/T SNPs in IL-4 were detected by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). </plain></SENT>
<SENT sid="49" pm="."><plain>Primers and probes were designed by Sangon Biotech Company (Shanghai, China). </plain></SENT>
<SENT sid="50" pm="."><plain>The primer sequences, annealing temperature, length of the PCR products, and corresponding restriction enzyme used for genotyping are presented in Table S1. </plain></SENT>
<SENT sid="51" pm="."><plain>After amplification, the PCR product was digested by restriction enzyme, visualized on a 2.5% agarose gel, and stained with ethidium bromide (Promega Corporation, Madison, WI, USA) for genotyping (Figure 1). </plain></SENT>
<SENT sid="52" pm="."><plain>The genotyping was performed for all participants under blinded conditions. </plain></SENT>
<SENT sid="53" pm="."><plain>For quality control, 50% of samples were repeated and direct sequencing was also performed by Sangon Biotech Company using 10% randomly selected samples (Figures 2 and 3); a 100% concordance rate was achieved. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="pone-0110061-g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0110061.g001</object-id><label>Figure 1</label><caption><title><text><SENT sid="54" pm="."><plain>PCR-RFLP assay for analyzing the IL-4−589C/T and −33C/T polymorphisms of the IL-4 gene. </plain></SENT>
</text></title><p><text><SENT sid="55" pm="."><plain>PCR product was digested by restriction enzyme and visualized on a 2.5% agarose gel. a −589C/T polymorphism. </plain></SENT>
<SENT sid="56" pm="."><plain>Lanes 1 and 2 show CC genotype; lanes 3, 4 and 5 show TT genotype; lanes 6 and 7 show CT genotype. b −33C/T polymorphism. </plain></SENT>
<SENT sid="57" pm="."><plain>Lanes 1, 2 and 3 show TT genotype; lanes 4 and 5 show CC genotype; lanes 6 and 7 show CT genotype. </plain></SENT>
<SENT sid="58" pm="."><plain>M, marker. </plain></SENT>
</text></p></caption><graphic xlink:href="pone.0110061.g001"/></fig></SecTag><SecTag type="FIG"><fig id="pone-0110061-g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0110061.g002</object-id><label>Figure 2</label><caption><title><text><SENT sid="59" pm="."><plain>Sequencing map of the genotype for the IL-4−589C/T polymorphism. </plain></SENT>
</text></title><p><text><SENT sid="60" pm="."><plain>Arrow in parts a−c indicates CC, TT and C/T genotypes, respectively. </plain></SENT>
</text></p></caption><graphic xlink:href="pone.0110061.g002"/></fig></SecTag><SecTag type="FIG"><fig id="pone-0110061-g003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0110061.g003</object-id><label>Figure 3</label><caption><title><text><SENT sid="61" pm="."><plain>Sequencing map of the genotype for the IL-4−33C/T polymorphisms. </plain></SENT>
</text></title><p><text><SENT sid="62" pm="."><plain>Arrow in parts a−c indicates CC, TT and C/T genotypes, respectively. </plain></SENT>
</text></p></caption><graphic xlink:href="pone.0110061.g003"/></fig></SecTag></sec><sec id="s2c"><title><text><SENT sid="63" pm="."><plain>Statistical analysis </plain></SENT>
</text></title><p><text><SENT sid="64" pm="."><plain>The statistical analyses were performed using the statistical software package SPSS 16.0 (SPSS Inc., Chicago, IL, USA). </plain></SENT>
<SENT sid="65" pm="."><plain>The Hardy-Weinberg equilibrium (HWE) was firstly tested with a goodness-of-fit χ2 test. </plain></SENT>
<SENT sid="66" pm="."><plain>General characteristics among the four groups were determined via Analysis of Variance (ANOVA) and the allele frequency and genotype distribution of IL-4 gene polymorphisms were compared using the χ2 test and Fisher’s exact test, when appropriate. </plain></SENT>
<SENT sid="67" pm="."><plain>Binary logistic regression was used to calculate the odds ratios (ORs) and 95% confidence intervals (CIs) after age and gender status adjustments. </plain></SENT>
<SENT sid="68" pm="."><plain>Globally, HCC rates are more than twice as high in males as in females [25] and, therefore, gender may be a possible confounder. </plain></SENT>
<SENT sid="69" pm="."><plain>Thus, a stratification of the study population into males and females was further performed to evaluate the association within each stratum. </plain></SENT>
<SENT sid="70" pm="."><plain>Considering the possible linkage disequilibrium between the polymorphisms, Shi’s standardized coefficient D’ was used for quantification [26]; using the Phase program [27], [28], haplotypes and their frequencies were also estimated based on a Bayesian algorithm. </plain></SENT>
<SENT sid="71" pm="."><plain>All significance tests were two-sided, and P&lt;0.05 was considered a statistically significant difference. </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="RESULTS"><sec id="s3"><title><text><SENT sid="72" pm="."><plain>Results </plain></SENT>
</text></title><sec id="s3a"><title><text><SENT sid="73" pm="."><plain>Characteristics of the study participants </plain></SENT>
</text></title><p><text><SENT sid="74" pm="."><plain>Table 1 summarizes the basic characteristics of the 170 healthy controls and the 129 CHB, 62 LC, and 154 HCC patients. </plain></SENT>
<SENT sid="75" pm="."><plain>Briefly, the LC and HCC patients were, on average, 10 years older than CHB patients and healthy controls, with the difference being statistically significant (both P&lt;0.001). </plain></SENT>
<SENT sid="76" pm="."><plain>As for gender distribution, there were no significant differences between the case and control groups (P = 0.488, P = 0.618, and P = 0.751, respectively). </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="pone-0110061-t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0110061.t001</object-id><label>Table 1</label><caption><title><text><SENT sid="77" pm="."><plain>Basic characteristic of the study population. </plain></SENT>
</text></title></caption><alternatives><graphic id="pone-0110061-t001-1" xlink:href="pone.0110061.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="78" pm="."><plain>Variable </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="79" pm="."><plain>HealthyControls(n = 170) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="80" pm="."><plain>CHB patients(n = 129) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="81" pm="."><plain>P-value </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="82" pm="."><plain>LC patients(n = 62) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="83" pm="."><plain>P-value </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="84" pm="."><plain>HCC patients(n = 154) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="85" pm="."><plain>P-value </plain></SENT>
</text></td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="86" pm="."><plain>Age(year, mean±SD) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="87" pm="."><plain>37.68±11.76 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="88" pm="."><plain>37.67±7.78 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="89" pm="."><plain>0.994 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="90" pm="."><plain>47.38±9.64 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="91" pm="."><plain>&lt;0.001 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="92" pm="."><plain>49.19±11.33 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="93" pm="."><plain>&lt;0.001 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="94" pm="."><plain>Gender, N(%) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="95" pm="."><plain>Male </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="96" pm="."><plain>147(86.5) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="97" pm="."><plain>115(89.1) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="98" pm="."><plain>0.488 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="99" pm="."><plain>52(83.9) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="100" pm="."><plain>0.618 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="101" pm="."><plain>135(87.7) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="102" pm="."><plain>0.751 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="103" pm="."><plain>Female </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="104" pm="."><plain>23(13.5) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="105" pm="."><plain>14(10.2) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="106" pm="."><plain>10(16.1) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="107" pm="."><plain>19(12.3) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/></tr></tbody></table></alternatives></table-wrap></SecTag></sec><sec id="s3b"><title><text><SENT sid="108" pm="."><plain>Genotype polymorphisms and the risk of HBV-related diseases </plain></SENT>
</text></title><p><text><SENT sid="109" pm="."><plain>The genotype and allele frequencies of the −589C/T and −33C/T IL-4 gene polymorphisms for patients with HBV-related diseases and healthy controls are shown in Table 2. </plain></SENT>
<SENT sid="110" pm="."><plain>According to the HWE test, the genotype distribution of the two SNPs in the patient groups and healthy controls were all agreed with HWE (P&gt;0.05 for all). </plain></SENT>
<SENT sid="111" pm="."><plain>However, no significant differences between the genotype and allele frequencies of the −589C/T and −33C/T IL-4 gene polymorphisms and CHB risk were observed. </plain></SENT>
<SENT sid="112" pm="."><plain>Binary logistic regression analyses adjusted for age and gender also failed to reveal any significant difference between them. </plain></SENT>
<SENT sid="113" pm="."><plain>Further, when considering LC and HCC patients, similar non-significant results were also found. </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="pone-0110061-t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0110061.t002</object-id><label>Table 2</label><caption><title><text><SENT sid="114" pm="."><plain>Genotype and allele frequencies of −589C/T and −33C/T polymorphisms between HBV-related patients and healthy controls. </plain></SENT>
</text></title></caption><alternatives><graphic id="pone-0110061-t002-2" xlink:href="pone.0110061.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="115" pm="."><plain>Polymorphisms </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="116" pm="."><plain>Healthycontrols,N = 170(%) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="117" pm="."><plain>CHBpatientsN = 129(%) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="118" pm="."><plain>LCpatients,N = 62(%) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="119" pm="."><plain>HCCpatients,N = 154(%) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="120" pm="."><plain>CHB patientsvs. </plain></SENT>
<SENT sid="121" pm="."><plain>Healthycontrols </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="122" pm="."><plain>LC patients vs.Healthy controls </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="123" pm="."><plain>HCC patientsvs. </plain></SENT>
<SENT sid="124" pm="."><plain>Healthycontrols </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td colspan="3" align="left" rowspan="1"><text><SENT sid="125" pm="."><plain>OR (95%CI)a </plain></SENT>
</text></td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="126" pm="."><plain>−589C/T </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="127" pm="."><plain>TT </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="128" pm="."><plain>115(67.6) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="129" pm="."><plain>77(59.7) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="130" pm="."><plain>37(59.7) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="131" pm="."><plain>111(72.1) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="132" pm="."><plain>1.00 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="133" pm="."><plain>1.00 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="134" pm="."><plain>1.00 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="135" pm="."><plain>CT </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="136" pm="."><plain>51(30.0) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="137" pm="."><plain>43(33.3) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="138" pm="."><plain>22(35.5) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="139" pm="."><plain>39(25.3) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="140" pm="."><plain>1.28(0.78–2.12) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="141" pm="."><plain>1.58(0.80–3.10) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="142" pm="."><plain>0.90(0.52–1.56) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="143" pm="."><plain>CC </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="144" pm="."><plain>4(2.4) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="145" pm="."><plain>9(7.0) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="146" pm="."><plain>3(4.8) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="147" pm="."><plain>4(2.6) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="148" pm="."><plain>3.35(0.99–11.28) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="149" pm="."><plain>2.10(0.39–11.34) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="150" pm="."><plain>1.13(0.26–5.06) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="151" pm="."><plain>Dominant modelb </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="152" pm="."><plain>55(32.4) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="153" pm="."><plain>52(40.3) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="154" pm="."><plain>25(40.3) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="155" pm="."><plain>43(27.9) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="156" pm="."><plain>1.44(0.89–2.33) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="157" pm="."><plain>1.56(0.81–2.99) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="158" pm="."><plain>0.921(0.54–1.56) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="159" pm="."><plain>Recessive modelc </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="160" pm="."><plain>166(97.6) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="161" pm="."><plain>120(93.0) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="162" pm="."><plain>59(95.2) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="163" pm="."><plain>150(97.4) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="164" pm="."><plain>3.08(0.93–10.25) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="165" pm="."><plain>1.92(0.87–7.36) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="166" pm="."><plain>1.17(0.27–5.13) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="167" pm="."><plain>T allele </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="168" pm="."><plain>281(82.6) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="169" pm="."><plain>197(76.4) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="170" pm="."><plain>96(77.4) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="171" pm="."><plain>261(84.7) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="172" pm="."><plain>1.00 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="173" pm="."><plain>1.00 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="174" pm="."><plain>1.00 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="175" pm="."><plain>C allele </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="176" pm="."><plain>59(17.4) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="177" pm="."><plain>61(23.6) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="178" pm="."><plain>28(22.6) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="179" pm="."><plain>47(15.3) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="180" pm="."><plain>1.49(0.99–2.23) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="181" pm="."><plain>1.51(0.87–2.61) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="182" pm="."><plain>0.95(0.60–1.51) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="183" pm="."><plain>P-HWE </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="184" pm="."><plain>0.550 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="185" pm="."><plain>0.383 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="186" pm="."><plain>0.907 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="187" pm="."><plain>0.796 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="188" pm="."><plain>−33C/T </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="189" pm="."><plain>TT </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="190" pm="."><plain>113(66.5) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="191" pm="."><plain>77(59.7) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="192" pm="."><plain>36(58.1) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="193" pm="."><plain>97(63.0) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="194" pm="."><plain>1.00 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="195" pm="."><plain>1.00 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="196" pm="."><plain>1.00 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="197" pm="."><plain>CT </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="198" pm="."><plain>52(30.6) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="199" pm="."><plain>42(32.6) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="200" pm="."><plain>22(35.4) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="201" pm="."><plain>49(31.9) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="202" pm="."><plain>1.21(0.73–2.00) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="203" pm="."><plain>1.59(0.81–3.13) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="204" pm="."><plain>1.29(0.76–2.20) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="205" pm="."><plain>CC </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="206" pm="."><plain>5(2.9) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="207" pm="."><plain>10(7.8) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="208" pm="."><plain>4(6.5) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="209" pm="."><plain>8(5.2) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="210" pm="."><plain>2.92(0.96–8.92) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="211" pm="."><plain>2.33(0.52–10.56) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="212" pm="."><plain>2.24(0.65–7.74) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="213" pm="."><plain>Dominant modelb </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="214" pm="."><plain>57(33.5) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="215" pm="."><plain>52(40.3) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="216" pm="."><plain>26(41.9) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="217" pm="."><plain>57(47.1) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="218" pm="."><plain>1.36(0.84–2.20) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="219" pm="."><plain>1.67(0.87–3.19) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="220" pm="."><plain>1.38(0.83–2.30) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="221" pm="."><plain>Recessive modelc </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="222" pm="."><plain>165(97.1) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="223" pm="."><plain>119(92.2) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="224" pm="."><plain>58(93.5) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="225" pm="."><plain>146(94.8) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="226" pm="."><plain>2.74(0.91–8.25) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="227" pm="."><plain>1.98(0.25–8.74) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="228" pm="."><plain>2.06(0.60–7.01) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="229" pm="."><plain>T allele </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="230" pm="."><plain>278(81.8) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="231" pm="."><plain>196(76.0) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="232" pm="."><plain>94(75.8) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="233" pm="."><plain>263(78.9) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="234" pm="."><plain>1.00 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="235" pm="."><plain>1.00 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="236" pm="."><plain>1.00 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="237" pm="."><plain>C allele </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="238" pm="."><plain>62(18.2) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="239" pm="."><plain>62(24.0) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="240" pm="."><plain>30(24.2) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="241" pm="."><plain>65(21.1) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="242" pm="."><plain>1.43(0.96–2.13) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="243" pm="."><plain>1.56(0.91–2.66) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="244" pm="."><plain>1.38(0.90–2.12) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="245" pm="."><plain>P-HWE </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="246" pm="."><plain>0.737 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="247" pm="."><plain>0.219 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="248" pm="."><plain>0.797 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="249" pm="."><plain>0.581 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt101"><label>a</label><p><text><SENT sid="250" pm="."><plain>Adjusted by age and gender; </plain></SENT>
</text></p></fn><fn id="nt102"><label>b</label><p><text><SENT sid="251" pm="."><plain>Dominant model: CT+CC versus TT; </plain></SENT>
</text></p></fn><fn id="nt103"><label>c</label><p><text><SENT sid="252" pm="."><plain>Recessive model: CC versus TT+CT. </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag><p><text><SENT sid="253" pm="."><plain>Nevertheless, when subgroup analyses between males and females were conducted, significant differences were found in males in the CC genotype in co-dominant genetic model CC versus TT and recessive genetic model CC versus TT+CT. </plain></SENT>
<SENT sid="254" pm="."><plain>Both 589C/T CC and −33C/T CC genotypes in males were associated with a significantly increased risk of CHB compared with the TT genotype (OR: 4.193, 95% CI: 1.094–16.071, and P = 0.037; and OR: 3.438, 95% CI: 1.032–11.458, and P = 0.044); similar situation was also found in the recessive model (OR: 4.09, 95% CI: 1.08–15.49, and P = 0.038; and OR: 3.43, 95% CI: 1.04–11.28, and P = 0.042) (Table 3). </plain></SENT>
<SENT sid="255" pm="."><plain>On the other hand, significant differences between case and control groups were not observed for any genotype in females (Table S2). </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="pone-0110061-t003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0110061.t003</object-id><label>Table 3</label><caption><title><text><SENT sid="256" pm="."><plain>Genotype and allele frequencies of −589C/T and −33C/T polymorphisms between HBV-related patients and healthy controls in males. </plain></SENT>
</text></title></caption><alternatives><graphic id="pone-0110061-t003-3" xlink:href="pone.0110061.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="257" pm="."><plain>Polymorphisms </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="258" pm="."><plain>Healthycontrols,N = 147(%) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="259" pm="."><plain>CHBpatientsN = 115(%) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="260" pm="."><plain>LCpatients,N = 52(%) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="261" pm="."><plain>HCCpatients,N = 135(%) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="262" pm="."><plain>CHB patients vs.Healthy controls,OR(95%CI)a </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="263" pm="."><plain>LC patients vs.Healthycontrols, OR(95%CI)a </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="264" pm="."><plain>HCC patientsvs. </plain></SENT>
<SENT sid="265" pm="."><plain>Healthycontrols, OR(95%CI)a </plain></SENT>
</text></td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="266" pm="."><plain>−589C/T </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="267" pm="."><plain>Genotypes </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="268" pm="."><plain>TT </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="269" pm="."><plain>100(68.0) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="270" pm="."><plain>72(62.6) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="271" pm="."><plain>31(59.6) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="272" pm="."><plain>95(70.4) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="273" pm="."><plain>1.00 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="274" pm="."><plain>1.00 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="275" pm="."><plain>1.00 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="276" pm="."><plain>CT </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="277" pm="."><plain>44(30.0) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="278" pm="."><plain>34(29.6) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="279" pm="."><plain>19(36.5) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="280" pm="."><plain>36(26.6) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="281" pm="."><plain>1.08(0.63–1.86) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="282" pm="."><plain>1.92(0.92–4.01) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="283" pm="."><plain>1.01(0.57–1.81) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="284" pm="."><plain>CC </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="285" pm="."><plain>3(2.0) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="286" pm="."><plain>9(7.8) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="287" pm="."><plain>2(3.9) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="288" pm="."><plain>4(3.0) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="289" pm="."><plain>4.19(1.09–16.07) * </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="290" pm="."><plain>2.83(0.42–18.88) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="291" pm="."><plain>1.59(0.32–7.98) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="292" pm="."><plain>Dominant modelb </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="293" pm="."><plain>47(32.0) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="294" pm="."><plain>43(37.4) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="295" pm="."><plain>21(40.4) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="296" pm="."><plain>40(29.6) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="297" pm="."><plain>1.28(0.76–2.15) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="298" pm="."><plain>1.98(0.99–4.08) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="299" pm="."><plain>1.05(0.60–1.85) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="300" pm="."><plain>Recessive modelc </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="301" pm="."><plain>144(98.0) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="302" pm="."><plain>106(92.2) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="303" pm="."><plain>50(96.1) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="304" pm="."><plain>131(97.0) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="305" pm="."><plain>4.09(1.08–15.49) * </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="306" pm="."><plain>2.23(0.35–14.43) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="307" pm="."><plain>1.58(0.32–7.88) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="308" pm="."><plain>T allele </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="309" pm="."><plain>244(83.0) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="310" pm="."><plain>178(77.4) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="311" pm="."><plain>81(77.9) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="312" pm="."><plain>226(83.7) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="313" pm="."><plain>1.00 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="314" pm="."><plain>1.00 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="315" pm="."><plain>1.00 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="316" pm="."><plain>C allele </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="317" pm="."><plain>50(17.0) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="318" pm="."><plain>52(22.6) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="319" pm="."><plain>23(22.1) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="320" pm="."><plain>44(16.3) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="321" pm="."><plain>1.43(0.93–2.06) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="322" pm="."><plain>1.76(0.97–3.18) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="323" pm="."><plain>1.085(0.67–1.77) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="324" pm="."><plain>−33C/T </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="325" pm="."><plain>Genotypes </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="326" pm="."><plain>TT </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="327" pm="."><plain>98(66.7) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="328" pm="."><plain>72(62.6) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="329" pm="."><plain>30(57.7) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="330" pm="."><plain>84(62.2) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="331" pm="."><plain>1.00 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="332" pm="."><plain>1.00 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="333" pm="."><plain>1.00 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="334" pm="."><plain>CT </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="335" pm="."><plain>45(30.6) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="336" pm="."><plain>33(28.7) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="337" pm="."><plain>19(36.5) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="338" pm="."><plain>43(31.9) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="339" pm="."><plain>1.01(0.58–1.74) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="340" pm="."><plain>1.84(0.89–3.82) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="341" pm="."><plain>1.37(0.78–2.43) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="342" pm="."><plain>CC </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="343" pm="."><plain>4(2.7) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="344" pm="."><plain>10(8.7) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="345" pm="."><plain>3(5.7) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="346" pm="."><plain>8(5.9) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="347" pm="."><plain>3.44(1.03–11.46) * </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="348" pm="."><plain>2.76(0.51–14.96) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="349" pm="."><plain>2.96(0.78–11.22) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="350" pm="."><plain>Dominant modelb </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="351" pm="."><plain>49(33.3) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="352" pm="."><plain>43(37.4) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="353" pm="."><plain>22(42.3) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="354" pm="."><plain>51(37.8) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="355" pm="."><plain>1.20(0.72–2.01) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="356" pm="."><plain>1.92(0.95–3.89) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="357" pm="."><plain>1.51(0.87–2.61) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="358" pm="."><plain>Recessive modelc </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="359" pm="."><plain>143(97.3) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="360" pm="."><plain>105(91.3) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="361" pm="."><plain>49(94.2) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="362" pm="."><plain>127(94.1) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="363" pm="."><plain>3.43(1.04–11.28) * </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="364" pm="."><plain>2.22(0.43–11.54) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="365" pm="."><plain>2.65(0.71–9.90) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="366" pm="."><plain>T allele </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="367" pm="."><plain>241(82.0) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="368" pm="."><plain>177(77.0) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="369" pm="."><plain>79(76.0) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="370" pm="."><plain>211(78.1) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="371" pm="."><plain>1.00 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="372" pm="."><plain>1.00 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="373" pm="."><plain>1.00 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="374" pm="."><plain>C allele </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="375" pm="."><plain>53(18.0) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="376" pm="."><plain>53(23.0) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="377" pm="."><plain>24(24.0) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="378" pm="."><plain>59(21.9) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="379" pm="."><plain>1.37(0.89–2.10) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="380" pm="."><plain>1.73(0.97–3.07) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="381" pm="."><plain>1.52(0.96–2.41) </plain></SENT>
</text></td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt104"><label>a</label><p><text><SENT sid="382" pm="."><plain>Adjusted by age and gender; </plain></SENT>
</text></p></fn><fn id="nt105"><label>b</label><p><text><SENT sid="383" pm="."><plain>Dominant model: CT+CC versus TT; </plain></SENT>
</text></p></fn><fn id="nt106"><label>c</label><p><text><SENT sid="384" pm="."><plain>Recessive model: CC versus TT+CT; </plain></SENT>
</text></p></fn><fn id="nt107"><label/><p><text><SENT sid="385" pm="."><plain>*p&lt;0.05. </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag><p><text><SENT sid="386" pm="."><plain>Considering that the IL-4 genetic background may be distinct between different populations, the genotype and allele frequencies of the two SNPs in our control group were further compared with those in different races from the Haplotype Map (HapMap) project (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih">http://www.ncbi.nlm.nih</ext-link>. gov/snp/) as well as in previous reports [29]. </plain></SENT>
<SENT sid="387" pm="."><plain>The data shown in Table 4 suggests that the distribution of the two SNPs in the present study is significantly different from that in JPT (Japanese in Tokyo) and CEU (Utah residents with northern and western European ancestry) populations. </plain></SENT>
<SENT sid="388" pm="."><plain>For the 589C/T polymorphism, the frequencies of genotype TT and allele T in JPT and CEU populations are significantly lower, and the rate of CC genotype and C allele are significantly higher. </plain></SENT>
<SENT sid="389" pm="."><plain>With respect to the −33C/T polymorphism, significant genotype differences between the present study and YRI (Yoruba in Ibadan) were also found. </plain></SENT>
<SENT sid="390" pm="."><plain>Further, there were significantly lower detection rates of the TT genotype and T allele and higher detection rates of the CC genotype and C allele in the JPT, CEU, and YRI populations when compared with our data. </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="pone-0110061-t004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0110061.t004</object-id><label>Table 4</label><caption><title><text><SENT sid="391" pm="."><plain>Comparison of genotype and allele frequencies in the healthy control subjects of our study and that from the HapMap project. </plain></SENT>
</text></title></caption><alternatives><graphic id="pone-0110061-t004-4" xlink:href="pone.0110061.t004"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="392" pm="."><plain>Polymorphisms </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="393" pm="."><plain>Samples, N </plain></SENT>
</text></td><td colspan="3" align="left" rowspan="1"><text><SENT sid="394" pm="."><plain>Genotype frequency, n(%) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td colspan="2" align="left" rowspan="1"><text><SENT sid="395" pm="."><plain>Alleles frequency, n(%) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="396" pm="."><plain>TT </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="397" pm="."><plain>CT </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="398" pm="."><plain>CC </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="399" pm="."><plain>P values </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="400" pm="."><plain>T </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="401" pm="."><plain>C </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="402" pm="."><plain>P values </plain></SENT>
</text></td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="403" pm="."><plain>−589C/T </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="404" pm="."><plain>Present study </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="405" pm="."><plain>170 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="406" pm="."><plain>115(67.6) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="407" pm="."><plain>51(30.0) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="408" pm="."><plain>4(2.4) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="409" pm="."><plain>281(82.6) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="410" pm="."><plain>59(17.4) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="411" pm="."><plain>HCB* </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="412" pm="."><plain>86 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="413" pm="."><plain>50(58.1) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="414" pm="."><plain>34(39.5) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="415" pm="."><plain>2(2.3) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="416" pm="."><plain>0.307 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="417" pm="."><plain>134(77.9) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="418" pm="."><plain>38(22.1) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="419" pm="."><plain>0.196 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="420" pm="."><plain>JPT* </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="421" pm="."><plain>170 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="422" pm="."><plain>90(52.9) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="423" pm="."><plain>66(38.8) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="424" pm="."><plain>14(8.2) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="425" pm="."><plain>0.005 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="426" pm="."><plain>246(72.4) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="427" pm="."><plain>94(27.6) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="428" pm="."><plain>0.001 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="429" pm="."><plain>CEU* </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="430" pm="."><plain>226 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="431" pm="."><plain>4(1.8) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="432" pm="."><plain>54(23.9) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="433" pm="."><plain>168(74.3) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="434" pm="."><plain>0.000 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="435" pm="."><plain>62(13.7) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="436" pm="."><plain>390(86.3) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="437" pm="."><plain>0.000 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="438" pm="."><plain>YRI* </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="439" pm="."><plain>226 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="440" pm="."><plain>140(61.9) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="441" pm="."><plain>76(33.6) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="442" pm="."><plain>10(4.4) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="443" pm="."><plain>0.356 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="444" pm="."><plain>356(78.8) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="445" pm="."><plain>96(21.2) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="446" pm="."><plain>0.172 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="447" pm="."><plain>Chinese† </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="448" pm="."><plain>151 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="449" pm="."><plain>92(60.9) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="450" pm="."><plain>50(33.1) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="451" pm="."><plain>9(6.0) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="452" pm="."><plain>0.185 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="453" pm="."><plain>234(77.5) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="454" pm="."><plain>68(22.5) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="455" pm="."><plain>0.101 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="456" pm="."><plain>−33C/T </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="457" pm="."><plain>Present study </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="458" pm="."><plain>170 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="459" pm="."><plain>113(66.5) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="460" pm="."><plain>52(30.6) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="461" pm="."><plain>5(2.9) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="462" pm="."><plain>278(81.8) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="463" pm="."><plain>62(18.2) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="464" pm="."><plain>HCB* </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="465" pm="."><plain>86 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="466" pm="."><plain>50(58.1) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="467" pm="."><plain>34(39.5) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="468" pm="."><plain>2(2.3) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="469" pm="."><plain>0.357 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="470" pm="."><plain>134(77.9) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="471" pm="."><plain>38(22.1) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="472" pm="."><plain>0.298 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="473" pm="."><plain>JPT* </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="474" pm="."><plain>172 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="475" pm="."><plain>90(52.3) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="476" pm="."><plain>68(39.5) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="477" pm="."><plain>14(8.1) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="478" pm="."><plain>0.011 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="479" pm="."><plain>248(72.1) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="480" pm="."><plain>96(27.9) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="481" pm="."><plain>0.003 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="482" pm="."><plain>CEU* </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="483" pm="."><plain>226 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="484" pm="."><plain>4(1.8) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="485" pm="."><plain>54(23.9) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="486" pm="."><plain>168(74.3) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="487" pm="."><plain>0.000 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="488" pm="."><plain>62(13.7) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="489" pm="."><plain>390(86.3) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="490" pm="."><plain>0.000 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="491" pm="."><plain>YRI* </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="492" pm="."><plain>226 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="493" pm="."><plain>44(19.5) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="494" pm="."><plain>126(55.8) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="495" pm="."><plain>56(24.8) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="496" pm="."><plain>0.000 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="497" pm="."><plain>214(47.3) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="498" pm="."><plain>238(52.7) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="499" pm="."><plain>0.000 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="500" pm="."><plain>HCH† </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="501" pm="."><plain>159 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="502" pm="."><plain>104(65.4) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="503" pm="."><plain>51(32.1) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="504" pm="."><plain>4(2.5) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="505" pm="."><plain>0.939 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="506" pm="."><plain>259(81.4) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="507" pm="."><plain>59(18.6) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="508" pm="."><plain>0.916 </plain></SENT>
</text></td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt108"><label/><p><text><SENT sid="509" pm="."><plain>*Data from HapMap Project; </plain></SENT>
</text></p></fn><fn id="nt109"><label>†</label><p><text><SENT sid="510" pm="."><plain>Data from previous reports; HCB, Han Chinese in Beijing, China; JPT, Japanese in Tokyo, Japan; CEU, Utah residents with northern and western European ancestry; YRI, Yoruba in Ibadan, Nigeria; HCH, Han Chinese in Hunan province, China. </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag></sec><sec id="s3c"><title><text><SENT sid="511" pm="."><plain>Estimated haplotype frequencies and the risk of HBV-related diseases </plain></SENT>
</text></title><p><text><SENT sid="512" pm="."><plain>Haplotype analyses were performed for all patient groups and healthy controls using the SHEsis software, and the four possible haplotype frequencies of the two SNPs are shown in Table 5. </plain></SENT>
<SENT sid="513" pm="."><plain>According to the results, the T−589 T−33 haplotype is the most common haplotype and represents &gt;50% in all groups, whereas the C−589 C−33 haplotype accounts for 14.9% to 23.3% among the four groups and represents the second highest haplotype. </plain></SENT>
<SENT sid="514" pm="."><plain>After haplotype analyses, however, no significant differences in these haplotype frequencies were found in any group. </plain></SENT>
<SENT sid="515" pm="."><plain>Finally, C−589 T−33 and T−589 C−33 are rare haplotypes that account for less than 2% in the control subjects and therefore further analyses were not conducted for these. </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="pone-0110061-t005" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0110061.t005</object-id><label>Table 5</label><caption><title><text><SENT sid="516" pm="."><plain>Frequencies of the haplotypes formed by −589C/T and −33C/T polymorphisms in HBV-related patients and healthy controls. </plain></SENT>
</text></title></caption><alternatives><graphic id="pone-0110061-t005-5" xlink:href="pone.0110061.t005"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="517" pm="."><plain>Haplotype </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="518" pm="."><plain>Healthycontrol(%) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="519" pm="."><plain>CHBPatients(%) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="520" pm="."><plain>OR(95%CI) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="521" pm="."><plain>p </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="522" pm="."><plain>LCPatients(%) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="523" pm="."><plain>OR(95%CI) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="524" pm="."><plain>p </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="525" pm="."><plain>HCCPatients(%) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="526" pm="."><plain>OR(95%CI) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="527" pm="."><plain>p </plain></SENT>
</text></td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="528" pm="."><plain>CC </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="529" pm="."><plain>17.1 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="530" pm="."><plain>23.3 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="531" pm="."><plain>1.47(0.98–2.20) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="532" pm="."><plain>0.061 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="533" pm="."><plain>16.5 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="534" pm="."><plain>0.96(0.55–1.66) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="535" pm="."><plain>0.878 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="536" pm="."><plain>14.9 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="537" pm="."><plain>0.85(0.56–1.30) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="538" pm="."><plain>0.459 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="539" pm="."><plain>CT </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="540" pm="."><plain>0.3 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="541" pm="."><plain>0.4 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="542" pm="."><plain>- </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="543" pm="."><plain>- </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="544" pm="."><plain>6.1 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="545" pm="."><plain>- </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="546" pm="."><plain>- </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="547" pm="."><plain>0.3 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="548" pm="."><plain>- </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="549" pm="."><plain>- </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="550" pm="."><plain>TC </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="551" pm="."><plain>1.2 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="552" pm="."><plain>0.8 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="553" pm="."><plain>- </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="554" pm="."><plain>- </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="555" pm="."><plain>7.7 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="556" pm="."><plain>- </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="557" pm="."><plain>- </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="558" pm="."><plain>6.2 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="559" pm="."><plain>- </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="560" pm="."><plain>- </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="561" pm="."><plain>TT </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="562" pm="."><plain>81.5 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="563" pm="."><plain>75.6 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="564" pm="."><plain>0.68(0.45–1.02) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="565" pm="."><plain>0.061 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="566" pm="."><plain>69.7 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="567" pm="."><plain>0.52(0.33–0.84) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="568" pm="."><plain>0.064 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="569" pm="."><plain>78.6 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="570" pm="."><plain>0.83(0.57–1.23) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="571" pm="."><plain>0.356 </plain></SENT>
</text></td></tr></tbody></table></alternatives></table-wrap></SecTag></sec></sec></SecTag><SecTag type="DISCUSS"><sec id="s4"><title><text><SENT sid="572" pm="."><plain>Discussion </plain></SENT>
</text></title><p><text><SENT sid="573" pm="."><plain>China, a region with 94 million HBsAg carriers, accounts for 50% of the total HCC cases worldwide [30], [31]. </plain></SENT>
<SENT sid="574" pm="."><plain>The predominant mode of HBV transmission in this hyperendemic region is vertical transmission from infected mothers during or shortly after birth [32]. </plain></SENT>
<SENT sid="575" pm="."><plain>However, only 5% to 10% of perinatally-infected infants become persistent carriers as adults, despite the approximately 90% risk; further, from these persistent infectors, 10% to 30% will progress to LC and HCC [33]. </plain></SENT>
<SENT sid="576" pm="."><plain>Such highly variable disease outcomes cannot be fully explained by differences in immunological, viral, or environmental factors. </plain></SENT>
<SENT sid="577" pm="."><plain>Thus, differences in host genetic factors may play essential roles in these processes. </plain></SENT>
</text></p><p><text><SENT sid="578" pm="."><plain>IL-4, a typical pleiotropic Th2 cytokine [9], is best known for defining the Th2 phenotype of lymphocytes, as well as being involved in regulating cell proliferation, apoptosis, and expression of numerous genes in lymphocytes, macrophages, and fibroblasts, among others [34]–[39]. </plain></SENT>
<SENT sid="579" pm="."><plain>Functional variations in this gene may contribute to viral clearance as well as HBV-associated HCC in high-risk Chinese patients. </plain></SENT>
<SENT sid="580" pm="."><plain>However, in the present study, we did not observe any association of IL-4 genotypes, alleles, and haplotypes with the overall CHB, LC, and HCC patients. </plain></SENT>
<SENT sid="581" pm="."><plain>Nevertheless, in subgroup analysis, CC genotypes of the IL-4 −589C/T and −33C/T polymorphisms were observed to be significantly associated with CHB in males as compared with the TT genotypes and TT+CT genotypes. </plain></SENT>
<SENT sid="582" pm="."><plain>In females, a similar trend towards an increased risk effect of CC genotypes in CHB was also observed, but the difference was not significant. </plain></SENT>
<SENT sid="583" pm="."><plain>These results indicate that IL-4 gene polymorphisms may be a risk factor for CHB in the Chinese male population only. </plain></SENT>
</text></p><p><text><SENT sid="584" pm="."><plain>Data from previous epidemiological studies was consistent with our results. </plain></SENT>
<SENT sid="585" pm="."><plain>In a meta-analysis conducted by Zheng et al. [20] exploring the IL-4 590C/T polymorphism and its susceptibility to liver disease (including HBV infection, HCV infection, liver cirrhosis, etc.), significant associations between the IL-4 590T polymorphism and increased risk of liver diseases was found in Caucasian populations, but not in Asian populations. </plain></SENT>
<SENT sid="586" pm="."><plain>Another meta-analysis investigating the association of IL-4 polymorphisms with response to HBV vaccine and susceptibility to HBV infection, also found no evidence indicating a correlation between IL-4 polymorphisms (rs2243250 C&gt;T) and susceptibility to HBV infection [21]. </plain></SENT>
<SENT sid="587" pm="."><plain>It is noted that all “Asian population” studies included in the two meta-analyses mentioned above were conducted in China [40]–[45]. </plain></SENT>
</text></p><p><text><SENT sid="588" pm="."><plain>It is noteworthy that, in the present study, the significant association between CHB in males was found in the CC genotypes of −589C/T and −33C/T polymorphisms, as opposed to the T allele in the Caucasian populations studied in the meta-analysis of Zheng et al. [20]. </plain></SENT>
<SENT sid="589" pm="."><plain>The fact that the same polymorphism site has distinct genotype frequencies which play different roles in the same disease may be principally explained by differences in the IL-4 genetic background among ethnicities; results from the comparison of genotype and allele frequencies in the healthy control subjects in the present study and those from the HapMap project provide evidence to this effect. </plain></SENT>
<SENT sid="590" pm="."><plain>In the current study, the IL-4 −590T and −33T allele frequencies among healthy controls were 82.6% and 81.8%, respectively, which were significantly higher than those observed in healthy Caucasians (both were 13.7%), while the C allele frequencies accounted for 17.4% in −590C/T mutations and 18.2% in −33C/T mutations, which were significantly lower than in Caucasians (both were 86.3%). </plain></SENT>
<SENT sid="591" pm="."><plain>Thus, the T allele may be the major allele in −589C/T and −33C/T SNPs in the Chinese population, and the C allele is the variant responsible for various diseases, while the opposite is true for Caucasians. </plain></SENT>
</text></p><p><text><SENT sid="592" pm="."><plain>With respect to HCC, only two studies were found regarding the IL-4 −590 C/T polymorphism and HCC risk in a high-risk Chinese population [46] and in low-risk non-Asians in the USA [22], both conducted by Ognjanovic et al. [22], [46]. </plain></SENT>
<SENT sid="593" pm="."><plain>Contrary to our results, the authors noted a substantial decrease in HCC risk associated with the IL-4 −590 CC genotype in Guangxi, China, and a non-significant result in Los Angeles non-Asians. </plain></SENT>
<SENT sid="594" pm="."><plain>However, in the present study, no association was found for either IL-4 −590C/T or −33C/T polymorphisms and HCC risk in the Chinese population. </plain></SENT>
<SENT sid="595" pm="."><plain>Drinking status may be a possible factor in the disparate associations between our study and theirs. </plain></SENT>
<SENT sid="596" pm="."><plain>According to their results [46], the IL-4 −590 CC genotype was not associated with a lower risk of HCC when initially adjusted for age, gender, and ethnicity (CC vs. CT/TT, OR: 0.46, 95% CI: 0.16–1.31); however, after further adjustment for HBsAg seropositivity and the number of alcoholic drinks per day (0, &lt;3, or &gt;3), the CC genotype was found to be negatively associated with HCC risk (CC vs. CT/TT, OR: 0.05, 95% CI: 0.01–0.40); in contrast, individuals included in our study were all HBsAg seropositive. </plain></SENT>
<SENT sid="597" pm="."><plain>In addition, the difference in study design and sample size may also be possible confounders. </plain></SENT>
</text></p><p><text><SENT sid="598" pm="."><plain>For IL-4 polymorphism haplotypes, previous experimental data has demonstrated some to be associated with respiratory syncytial virus [47], multiple sclerosis [48], oral cancer [49], and systemic lupus erythematosus [50], suggesting that certain important polymorphisms could affect the regulation of this cytokine. </plain></SENT>
<SENT sid="599" pm="."><plain>In addition, the T allele of the IL-4 −590C/T polymorphism has been reported to be in linkage disequilibrium with −33T [51], and was associated with an increased expression of IL-4 [52]. </plain></SENT>
<SENT sid="600" pm="."><plain>However, we did not find an association between any of the estimated haplotype frequencies and the risk of HBV-related diseases, indicating that the IL-4 gene haplotypes may not play any facilitative role in the development of HCC. </plain></SENT>
</text></p><p><text><SENT sid="601" pm="."><plain>In conclusion, we could not detect an effect of genetic variants between IL-4 and HBV-related HCC in a Chinese population. </plain></SENT>
<SENT sid="602" pm="."><plain>Interestingly, in subgroup analysis, the CC genotype of IL-4 −589C/T and −33C/T polymorphisms were observed to be significantly correlated with the risk of CHB in the Chinese male population. </plain></SENT>
<SENT sid="603" pm="."><plain>However, considering the relatively small sample size of this study, more studies with a larger sample size are warranted in an attempt to confirm the observed association. </plain></SENT>
</text></p></sec></SecTag><SecTag type="SUPPL"><sec sec-type="supplementary-material" id="s5"><title><text><SENT sid="604" pm="."><plain>Supporting Information </plain></SENT>
</text></title><supplementary-material content-type="local-data" id="pone.0110061.s001"><label>Table S1</label><caption><p><text><SENT sid="605" pm="."><plain>The sequences of forward and backward primers and restriction enzymes for genotyping IL-4 polymorphisms. </plain></SENT>
</text></p><p><text><SENT sid="606" pm="."><plain>(DOCX) </plain></SENT>
</text></p></caption><media xlink:href="pone.0110061.s001.docx"><caption><p><text><SENT sid="607" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0110061.s002"><label>Table S2</label><caption><p><text><SENT sid="608" pm="."><plain>Genotype and allele frequencies of −589C/T and −33C/T polymorphisms between HBV-related patients and healthy controls in females. </plain></SENT>
</text></p><p><text><SENT sid="609" pm="."><plain>(DOCX) </plain></SENT>
</text></p></caption><media xlink:href="pone.0110061.s002.docx"><caption><p><text><SENT sid="610" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material></sec></SecTag></body><back><SecTag type="REF"><ref-list><title>References</title><ref id="pone.0110061-Liaw1"><text><SENT sid="611" pm="."><plain>1 LiawYF, ChuCM (2009) Hepatitis B virus infection. Lancet 373: 582–592.19217993 </plain></SENT>
</text></ref><ref id="pone.0110061-Lavanchy1"><text><SENT sid="612" pm="."><plain>2 LavanchyD (2005) Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention. J Clin Virol 34 Suppl 1 S1–3. </plain></SENT>
</text></ref><ref id="pone.0110061-Perz1"><text><SENT sid="613" pm="."><plain>3 PerzJF, ArmstrongGL, FarringtonLA, HutinYJ, BellBP (2006) The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 45: 529–538.16879891 </plain></SENT>
</text></ref><ref id="pone.0110061-Yin1"><text><SENT sid="614" pm="."><plain>4 YinJ, XieJ, LiuS, ZhangH, HanL, et al (2011) Association between the various mutations in viral core promoter region to different stages of hepatitis B, ranging of asymptomatic carrier state to hepatocellular carcinoma. Am J Gastroenterol 106: 81–92.20959817 </plain></SENT>
</text></ref><ref id="pone.0110061-Chisari1"><text><SENT sid="615" pm="."><plain>5 ChisariFV, FerrariC (1995) Hepatitis B virus immunopathogenesis. Annu Rev Immunol 13: 29–60.7612225 </plain></SENT>
</text></ref><ref id="pone.0110061-Chen1"><text><SENT sid="616" pm="."><plain>6 ChenL, ZhangQ, ChangW, DuY, ZhangH, et al (2012) Viral and host inflammation-related factors that can predict the prognosis of hepatocellular carcinoma. Eur J Cancer 48: 1977–1987.22325840 </plain></SENT>
</text></ref><ref id="pone.0110061-Chemin1"><text><SENT sid="617" pm="."><plain>7 CheminI, ZoulimF (2009) Hepatitis B virus induced hepatocellular carcinoma. Cancer Lett 286: 52–59.19147276 </plain></SENT>
</text></ref><ref id="pone.0110061-Han1"><text><SENT sid="618" pm="."><plain>8 HanYF, ZhaoJ, MaLY, YinJH, ChangWJ, et al (2011) Factors predicting occurrence and prognosis of hepatitis-B-virus-related hepatocellular carcinoma. World J Gastroenterol 17: 4258–4270.22090781 </plain></SENT>
</text></ref><ref id="pone.0110061-Durie1"><text><SENT sid="619" pm="."><plain>9 DurieFH, FoyTM, MastersSR, LamanJD, NoelleRJ (1994) The role of CD40 in the regulation of humoral and cell-mediated immunity. Immunol Today 15: 406–411.7524518 </plain></SENT>
</text></ref><ref id="pone.0110061-Landi1"><text><SENT sid="620" pm="."><plain>10 LandiS, BottariF, GemignaniF, Gioia-PatricolaL, GuinoE, et al (2007) Interleukin-4 and interleukin-4 receptor polymorphisms and colorectal cancer risk. Eur J Cancer 43: 762–768.17258448 </plain></SENT>
</text></ref><ref id="pone.0110061-Luzina1"><text><SENT sid="621" pm="."><plain>11 LuzinaIG, KeeganAD, HellerNM, RookGA, Shea-DonohueT, et al (2012) Regulation of inflammation by interleukin-4: a review of “alternatives”. J Leukoc Biol 92: 753–764.22782966 </plain></SENT>
</text></ref><ref id="pone.0110061-Gordon1"><text><SENT sid="622" pm="."><plain>12 GordonS (2003) Alternative activation of macrophages. Nat Rev Immunol 3: 23–35.12511873 </plain></SENT>
</text></ref><ref id="pone.0110061-Stein1"><text><SENT sid="623" pm="."><plain>13 SteinM, KeshavS, HarrisN, GordonS (1992) Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. J Exp Med 176: 287–292.1613462 </plain></SENT>
</text></ref><ref id="pone.0110061-Capece1"><text><SENT sid="624" pm="."><plain>14 CapeceD, FischiettiM, VerzellaD, GaggianoA, CicciarelliG, et al (2013) The inflammatory microenvironment in hepatocellular carcinoma: a pivotal role for tumor-associated macrophages. Biomed Res Int 2013: 187204.23533994 </plain></SENT>
</text></ref><ref id="pone.0110061-Jiang1"><text><SENT sid="625" pm="."><plain>15 JiangH, HarrisMB, RothmanP (2000) IL-4/IL-13 signaling beyond JAK/STAT. J Allergy Clin Immunol 105: 1063–1070.10856136 </plain></SENT>
</text></ref><ref id="pone.0110061-Marsh1"><text><SENT sid="626" pm="."><plain>16 MarshDG, NeelyJD, BreazealeDR, GhoshB, FreidhoffLR, et al (1994) Linkage analysis of IL4 and other chromosome 5q31.1 markers and total serum immunoglobulin E concentrations. Science 264: 1152–1156.8178175 </plain></SENT>
</text></ref><ref id="pone.0110061-Naslednikova1"><text><SENT sid="627" pm="."><plain>17 NaslednikovaIO, KonenkovVI, RyazantsevaNV, NovitskiiVV, TkachenkoSB, et al (2007) Role of genetically determined production of immunoregulatory cytokines in immunopathogenesis of chronic viral hepatitides. Bull Exp Biol Med 143: 706–712.18239807 </plain></SENT>
</text></ref><ref id="pone.0110061-Aithal1"><text><SENT sid="628" pm="."><plain>18 AithalGP, RamsayL, DalyAK, SonchitN, LeathartJB, et al (2004) Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity. Hepatology 39: 1430–1440.15122773 </plain></SENT>
</text></ref><ref id="pone.0110061-Zhu1"><text><SENT sid="629" pm="."><plain>19 ZhuQR, GeYL, GuSQ, YuH, WangJS, et al (2005) Relationship between cytokines gene polymorphism and susceptibility to hepatitis B virus intrauterine infection. Chin Med J (Engl) 118: 1604–1609.16232344 </plain></SENT>
</text></ref><ref id="pone.0110061-Zheng1"><text><SENT sid="630" pm="."><plain>20 ZhengZ, LiX, LiZ, MaXC (2013) IL-4 -590C/T polymorphism and susceptibility to liver disease: a meta-analysis and meta-regression. DNA Cell Biol 32: 443–450.23768103 </plain></SENT>
</text></ref><ref id="pone.0110061-Cui1"><text><SENT sid="631" pm="."><plain>21 CuiW, SunCM, DengBC, LiuP (2013) Association of polymorphisms in the interleukin-4 gene with response to hepatitis B vaccine and susceptibility to hepatitis B virus infection: a meta-analysis. Gene 525: 35–40.23651591 </plain></SENT>
</text></ref><ref id="pone.0110061-Ognjanovic1"><text><SENT sid="632" pm="."><plain>22 OgnjanovicS, YuanJM, ChaptmanAK, FanY, YuMC (2009) Genetic polymorphisms in the cytokine genes and risk of hepatocellular carcinoma in low-risk non-Asians of USA. Carcinogenesis 30: 758–762.19126646 </plain></SENT>
</text></ref><ref id="pone.0110061-Lok1"><text><SENT sid="633" pm="."><plain>23 LokAS, McMahonBJ (2007) Chronic hepatitis B. Hepatology. 45: 507–539. </plain></SENT>
</text></ref><ref id="pone.0110061-Peng1"><text><SENT sid="635" pm="."><plain>24 PengQ, QinX, HeY, ChenZ, DengY, et al (2013) Association of IL27 gene polymorphisms and HBV-related hepatocellular carcinoma risk in a Chinese population. Infect Genet Evol 16: 1–4.23395794 </plain></SENT>
</text></ref><ref id="pone.0110061-Jemal1"><text><SENT sid="636" pm="."><plain>25 JemalA, BrayF (2011) Center MM, Ferlay J, Ward E, et al (2011) Global cancer statistics. CA Cancer J Clin 61: 69–90.21296855 </plain></SENT>
</text></ref><ref id="pone.0110061-Shi1"><text><SENT sid="637" pm="."><plain>26 ShiYY, HeL (2005) SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res 15: 97–98.15740637 </plain></SENT>
</text></ref><ref id="pone.0110061-Li1"><text><SENT sid="638" pm="."><plain>27 LiZ, ZhangZ, HeZ, TangW, LiT, et al (2009) A partition-ligation-combination-subdivision EM algorithm for haplotype inference with multiallelic markers: update of the SHEsis (<ext-link ext-link-type="uri" xlink:href="http://analysis.bio-x.cn">http://analysis.bio-x.cn</ext-link>). Cell Res. 19: 519–523. </plain></SENT>
</text></ref><ref id="pone.0110061-Stephens1"><text><SENT sid="639" pm="."><plain>28 StephensM, SmithNJ, DonnellyP (2001) A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 68: 978–989.11254454 </plain></SENT>
</text></ref><ref id="pone.0110061-TangZY1"><text><SENT sid="640" pm="."><plain>29 Tang ZYYQ, FengXL, ZhouL, ZhangYL, ChenB (2009) Association between IL-4 C+33T and serum levels of IL-4 and atherothrombotic cerebral infarction in Chinese Han. Stroke and nevous diseases 16: 11–14. </plain></SENT>
</text></ref><ref id="pone.0110061-Yin2"><text><SENT sid="641" pm="."><plain>30 YinJ, ZhangH, HeY, XieJ, LiuS, et al (2010) Distribution and hepatocellular carcinoma-related viral properties of hepatitis B virus genotypes in Mainland China: a community-based study. Cancer Epidemiol Biomarkers Prev 19: 777–786.20160279 </plain></SENT>
</text></ref><ref id="pone.0110061-Siegel1"><text><SENT sid="642" pm="."><plain>31 SiegelR, NaishadhamD, JemalA (2012) Cancer statistics, 2012. CA Cancer J Clin 62: 10–29.22237781 </plain></SENT>
</text></ref><ref id="pone.0110061-Yu1"><text><SENT sid="643" pm="."><plain>32 YuMC, YuanJM (2004) Environmental factors and risk for hepatocellular carcinoma. Gastroenterology 127: S72–78.15508106 </plain></SENT>
</text></ref><ref id="pone.0110061-Zeng1"><text><SENT sid="644" pm="."><plain>33 ZengZ (2014) Human genes involved in hepatitis B virus infection. World J Gastroenterol 20: 7696–7706.24976707 </plain></SENT>
</text></ref><ref id="pone.0110061-Nelms1"><text><SENT sid="645" pm="."><plain>34 NelmsK, KeeganAD, ZamoranoJ, RyanJJ, PaulWE (1999) The IL-4 receptor: signaling mechanisms and biologic functions. Annu Rev Immunol 17: 701–738.10358772 </plain></SENT>
</text></ref><ref id="pone.0110061-KellyWelch1"><text><SENT sid="646" pm="."><plain>35 Kelly-WelchA, HansonEM, KeeganAD (2005) Interleukin-13 (IL-13) pathway. Sci STKE 2005: cm8.16030286 </plain></SENT>
</text></ref><ref id="pone.0110061-Chomarat1"><text><SENT sid="647" pm="."><plain>36 ChomaratP, BanchereauJ (1998) Interleukin-4 and interleukin-13: their similarities and discrepancies. Int Rev Immunol 17: 1–52.9914942 </plain></SENT>
</text></ref><ref id="pone.0110061-KellyWelch2"><text><SENT sid="648" pm="."><plain>37 Kelly-WelchAE, HansonEM, BoothbyMR, KeeganAD (2003) Interleukin-4 and interleukin-13 signaling connections maps. Science 300: 1527–1528.12791978 </plain></SENT>
</text></ref><ref id="pone.0110061-LaPorte1"><text><SENT sid="649" pm="."><plain>38 LaPorteSL, JuoZS, VaclavikovaJ, ColfLA, QiX, et al (2008) Molecular and structural basis of cytokine receptor pleiotropy in the interleukin-4/13 system. Cell 132: 259–272.18243101 </plain></SENT>
</text></ref><ref id="pone.0110061-Iseki1"><text><SENT sid="650" pm="."><plain>39 IsekiM, Omori-MiyakeM, XuW, SunX, TakakiS, et al (2012) Thymic stromal lymphopoietin (TSLP)-induced polyclonal B-cell activation and autoimmunity are mediated by CD4+ T cells and IL-4. Int Immunol 24: 183–195.22281511 </plain></SENT>
</text></ref><ref id="pone.0110061-Chen2"><text><SENT sid="651" pm="."><plain>40 ChenTY, HsiehYS, WuTT, YangSF, WuCJ, et al (2007) Impact of serum levels and gene polymorphism of cytokines on chronic hepatitis C infection. Transl Res 150: 116–121.17656331 </plain></SENT>
</text></ref><ref id="pone.0110061-Gao1"><text><SENT sid="652" pm="."><plain>41 GaoQJ, LiuDW, ZhangSY, JiaM, WangLM, et al (2009) Polymorphisms of some cytokines and chronic hepatitis B and C virus infection. World J Gastroenterol 15: 5610–5619.19938203 </plain></SENT>
</text></ref><ref id="pone.0110061-Liu1"><text><SENT sid="653" pm="."><plain>42 LiuQ, LongH, WangJG, DuJH (2007) Relationship between genetic polymorphisms of interleukin-4 (IL-4), interleukin-4 receptor a chain with susceptibility to HBVinduced liver cirrhosis. Chin J Integr Tradit West Med Liver Dis 17: 211–213. </plain></SENT>
</text></ref><ref id="pone.0110061-Zhu2"><text><SENT sid="654" pm="."><plain>43 ZhuQR, GeYL, GuSQ, YuH, WangJS, et al (2005) Relationship between cytokines gene polymorphism and susceptibility to hepatitis B virus intrauterine infection. Chin Med J 26: 1604–1069. </plain></SENT>
</text></ref><ref id="pone.0110061-Wang1"><text><SENT sid="655" pm="."><plain>44 WangK, ShiCW, GaoY, YuZH, NingT, et al (2006) The association of IL-2 and IL-4 polymorphisms and hepatitis B in population of north China. Chin J Curr Adv Gen Surg 9: 171–176. </plain></SENT>
</text></ref><ref id="pone.0110061-Gao2"><text><SENT sid="656" pm="."><plain>45 GaoQJ, SunDX, ZhangYH, ChenSP, WangXH, et al (2012) Association of IL-4-589 polymorphisms with chronic hepatitis B and hepatitis C virus infection. Med Pharm J Chin People’s Liberation Army 24: 8–10. </plain></SENT>
</text></ref><ref id="pone.0110061-Nieters1"><text><SENT sid="657" pm="."><plain>46 NietersA, YuanJM, SunCL, ZhangZQ, StoehlmacherJ, et al (2005) Effect of cytokine genotypes on the hepatitis B virus-hepatocellular carcinoma association. Cancer 103: 740–748.15643599 </plain></SENT>
</text></ref><ref id="pone.0110061-Puthothu1"><text><SENT sid="658" pm="."><plain>47 PuthothuB, KruegerM, ForsterJ, HeinzmannA (2006) Association between severe respiratory syncytial virus infection and IL13/IL4 haplotypes. J Infect Dis 193: 438–441.16388492 </plain></SENT>
</text></ref><ref id="pone.0110061-Suppiah1"><text><SENT sid="659" pm="."><plain>48 SuppiahV, GorisA, AllozaI, HeggartyS, DuboisB, et al (2005) Polymorphisms in the interleukin-4 and IL-4 receptor genes and multiple sclerosis: a study in Spanish-Basque, Northern Irish and Belgian populations. Int J Immunogenet 32: 383–388.16313303 </plain></SENT>
</text></ref><ref id="pone.0110061-Tsai1"><text><SENT sid="660" pm="."><plain>49 TsaiMH, ChenWC, TsaiCH, HangLW, TsaiFJ (2005) Interleukin-4 gene, but not the interleukin-1 beta gene polymorphism, is associated with oral cancer. J Clin Lab Anal 19: 93–98.15900573 </plain></SENT>
</text></ref><ref id="pone.0110061-Wu1"><text><SENT sid="661" pm="."><plain>50 WuMC, HuangCM, TsaiJJ, ChenHY, TsaiFJ (2003) Polymorphisms of the interleukin-4 gene in chinese patients with systemic lupus erythematosus in Taiwan. Lupus 12: 21–25.12587822 </plain></SENT>
</text></ref><ref id="pone.0110061-Takabayashi1"><text><SENT sid="662" pm="."><plain>51 TakabayashiA, IharaK, SasakiY, KusuharaK, NishimaS, et al (1999) Novel polymorphism in the 5′-untranslated region of the interleukin-4 gene. J Hum Genet 44: 352–353.10496083 </plain></SENT>
</text></ref><ref id="pone.0110061-Wierenga1"><text><SENT sid="663" pm="."><plain>52 WierengaEA, MesserG (2000) Regulation of interleukin 4 gene transcription: alterations in atopic disease? Am J Respir Crit Care Med 162: S81–85.10988157 </plain></SENT>
</text></ref></ref-list></SecTag></back></article>
